Mutation of the Plasmodium falciparum Flavokinase Confers Resistance to Roseoflavin and 8-Aminoriboflavin
- 26 June 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (8) , 2939-2949
Abstract
The riboflavin analogues, roseoflavin and 8-aminoriboflavin, inhibit malaria parasite proliferation by targeting riboflavin utilization. To determine their mechanism of action, we generated roseoflavin-resistant parasites by in vitro evolution. Relative to wild-type, these parasites were 4-fold resistant to roseoflavin and cross-resistant to 8-aminoriboflavin. Whole genome sequencing of the resistant parasites revealed a missense mutation leading to an amino acid change (L672H) in the gene coding for a putative flavokinase (PfFK), the enzyme responsible for converting riboflavin into the cofactor flavin mononucleotide (FMN). To confirm that the L672H mutation is responsible for the phenotype, we generated parasites with the missense mutation incorporated into the PfFK gene. The IC50 values for roseoflavin and 8-aminoriboflavin against the roseoflavin-resistant parasites created through in vitro evolution were indistinguishable from those against parasites in which the missense mutation was introduced into the native PfFK. We also generated two parasite lines episomally expressing GFP-tagged versions of either the wild-type or mutant forms of PfFK. We found that PfFK-GFP localizes to the parasite cytosol and that immunopurified PfFK-GFP phosphorylated riboflavin, roseoflavin, and 8-aminoriboflavin. The L672H mutation increased the KM for roseoflavin, explaining the resistance phenotype. Mutant PfFK is no longer capable of phosphorylating 8-aminoriboflavin, but its antiplasmodial activity against resistant parasites can still be antagonized by increasing the extracellular concentration of riboflavin, consistent with it also inhibiting parasite growth through competitive inhibition of PfFK. Our findings, therefore, are consistent with roseoflavin and 8-aminoriboflavin inhibiting parasite proliferation by inhibiting riboflavin phosphorylation and via the generation of toxic flavin cofactor analogues.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (IRTG 2290)
- Australian Government
- Australian National University (IRTG 2290)
This publication has 51 references indexed in Scilit:
- CRISPR/Cas9 Editing of the Plasmodium falciparum Genome2022
- Catalytic, kinetic and thermodynamic properties of free and immobilized caseinase on mica glass-ceramicsHeliyon, 2019
- The biochemistry of Plasmodium falciparum2016
- PROMALS3D: Multiple Protein Sequence Alignment Enhanced with Evolutionary and Three-Dimensional Structural Information2013
- Studies with the Plasmodium falciparum hexokinase reveal that PfHT limits the rate of glucose entry into glycolysisFEBS Letters, 2013
- Key Residues at the Riboflavin Kinase Catalytic Site of the Bifunctional Riboflavin Kinase/FMN Adenylyltransferase From Corynebacterium ammoniagenesCell Biochemistry and Biophysics, 2012
- The antibiotics roseoflavin and 8-demethyl-8-amino-riboflavin from Streptomyces davawensis are metabolized by human flavokinase and human FAD synthetaseBiochemical Pharmacology, 2011
- Cloning of Plasmodium falciparum by single-cell sortingExperimental Parasitology, 2010
- Plasmodium falciparum culture: The benefits of shakingMolecular and Biochemical Parasitology, 2010
- Quinoline anti‐malarial drugs inhibit spontaneous formation of β‐haematin (malaria pigment)FEBS Letters, 1994